Literature DB >> 25224000

In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with β-lactamase inhibitors.

Yasuhiro Horita1, Shinji Maeda2, Yuko Kazumi2, Norio Doi3.   

Abstract

We evaluated the antituberculosis (anti-TB) activity of five β-lactams alone or in combination with β-lactamase inhibitors against 41 clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains. Of those, tebipenem, an oral carbapenem, showed the most potent anti-TB activity against clinical isolates, with a MIC range of 0.125 to 8 μg/ml, which is achievable in the human blood. More importantly, in the presence of clavulanate, MIC values of tebipenem declined to 2 μg/ml or less.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25224000      PMCID: PMC4249422          DOI: 10.1128/AAC.03539-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Recent advances in tuberculosis: New drugs and treatment regimens.

Authors:  Derek J Sloan; Geraint R Davies; Saye H Khoo
Journal:  Curr Respir Med Rev       Date:  2013-06-01

2.  Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.

Authors:  Saverio De Lorenzo; Jan Wilem Alffenaar; Giovanni Sotgiu; Rosella Centis; Lia D'Ambrosio; Simon Tiberi; Mathieu S Bolhuis; Richard van Altena; Piero Viggiani; Andrea Piana; Antonio Spanevello; Giovanni Battista Migliori
Journal:  Eur Respir J       Date:  2012-09-20       Impact factor: 16.671

Review 3.  World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?

Authors:  Kelly E Dooley; Ekwaro A Obuku; Nadza Durakovic; Vera Belitsky; Carole Mitnick; Eric L Nuermberger
Journal:  J Infect Dis       Date:  2012-07-17       Impact factor: 5.226

4.  Clavulanic acid and amoxycillin: a clinical, bacteriological, and pharmacological study.

Authors:  A P Ball; A M Geddes; P G Davey; I D Farrell; G R Brookes
Journal:  Lancet       Date:  1980-03-22       Impact factor: 79.321

5.  Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology.

Authors:  J D van Embden; M D Cave; J T Crawford; J W Dale; K D Eisenach; B Gicquel; P Hermans; C Martin; R McAdam; T M Shinnick
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

6.  Inactivation of Mycobacterium tuberculosis l,d-transpeptidase LdtMt₁ by carbapenems and cephalosporins.

Authors:  Vincent Dubée; Sébastien Triboulet; Jean-Luc Mainardi; Mélanie Ethève-Quelquejeu; Laurent Gutmann; Arul Marie; Lionel Dubost; Jean-Emmanuel Hugonnet; Michel Arthur
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

7.  Dual-probe assay for rapid detection of drug-resistant Mycobacterium tuberculosis by real-time PCR.

Authors:  Takayuki Wada; Shinji Maeda; Aki Tamaru; Shigeyoshi Imai; Atsushi Hase; Kazuo Kobayashi
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

8.  Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate.

Authors:  Ximena Gonzalo; Francis Drobniewski
Journal:  J Antimicrob Chemother       Date:  2012-10-15       Impact factor: 5.790

9.  In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis.

Authors:  Suresh Solapure; Neela Dinesh; Radha Shandil; Vasanthi Ramachandran; Sreevalli Sharma; Deepa Bhattacharjee; Samit Ganguly; Jitendar Reddy; Vijaykamal Ahuja; Vijender Panduga; Manish Parab; K G Vishwas; Naveen Kumar; Meenakshi Balganesh; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

10.  [Clinical efficacy, safety and PK-PD analysis of tebipenem pivoxil in a phase II clinical trial in otolaryngological infections].

Authors:  Shunkichi Baba; Noboru Yamanaka; Kenji Suzuki; Mitsuru Furukawa; Nobuhiko Furuya; Kimiko Ubukata; Kyoichi Totsuka
Journal:  Jpn J Antibiot       Date:  2009-04
View more
  16 in total

1.  Revisiting the β-Lactams for Tuberculosis Therapy with a Compound-Compound Synthetic Lethality Approach.

Authors:  Shiqi Xiao; Haidan Guo; Warren S Weiner; Clinton Maddox; Chunhong Mao; Hendra Gunosewoyo; Shaaretha Pelly; E Lucile White; Lynn Rasmussen; Frank J Schoenen; Jeffrey Aubé; William R Bishai; Shichun Lun
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

2.  Mutation in an Unannotated Protein Confers Carbapenem Resistance in Mycobacterium tuberculosis.

Authors:  Pankaj Kumar; Amit Kaushik; Drew T Bell; Varsha Chauhan; Fangfang Xia; Rick L Stevens; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

3.  Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis.

Authors:  Sander P van Rijn; Marlanka A Zuur; Richard Anthony; Bob Wilffert; Richard van Altena; Onno W Akkerman; Wiel C M de Lange; Tjip S van der Werf; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

4.  Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus.

Authors:  Amit Kaushik; Nayani Makkar; Pooja Pandey; Nicole Parrish; Urvashi Singh; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

Review 5.  Drug-Resistant Tuberculosis: Challenges and Progress.

Authors:  Sebastian G Kurz; Jennifer J Furin; Charles M Bark
Journal:  Infect Dis Clin North Am       Date:  2016-06       Impact factor: 5.982

Review 6.  β-Lactam Resistance Mechanisms: Gram-Positive Bacteria and Mycobacterium tuberculosis.

Authors:  Jed F Fisher; Shahriar Mobashery
Journal:  Cold Spring Harb Perspect Med       Date:  2016-05-02       Impact factor: 6.915

7.  In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates.

Authors:  Dan Zhang; Yufeng Wang; Jie Lu; Yu Pang
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

8.  In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.

Authors:  Amit Kaushik; Nicole C Ammerman; Rokeya Tasneen; Elizabeth Story-Roller; Kelly E Dooley; Susan E Dorman; Eric L Nuermberger; Gyanu Lamichhane
Journal:  J Antimicrob Chemother       Date:  2017-08-01       Impact factor: 5.790

Review 9.  Have we realized the full potential of β-lactams for treating drug-resistant TB?

Authors:  Elizabeth Story-Roller; Gyanu Lamichhane
Journal:  IUBMB Life       Date:  2018-06-22       Impact factor: 3.885

10.  Combinations of β-Lactam Antibiotics Currently in Clinical Trials Are Efficacious in a DHP-I-Deficient Mouse Model of Tuberculosis Infection.

Authors:  Joaquín Rullas; Neeraj Dhar; John D McKinney; Adolfo García-Pérez; Joël Lelievre; Andreas H Diacon; Jean-Emmanuel Hugonnet; Michel Arthur; Iñigo Angulo-Barturen; David Barros-Aguirre; Lluís Ballell
Journal:  Antimicrob Agents Chemother       Date:  2015-05-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.